Why the study?
Efforts to extrapolate animal data on the cardiostimulant effects of glucagon to patients with low cardiac output states, such as acute heart failure or cardiogenic shock, have been disappointing.
Does glucagon have a positive inotropic effect in the human heart?
Does glucagon have a positive inotropic effect in the human heart?
Glucagon should not be used as an inotropic agent for low cardiac output states like acute heart failure, but its chronotropic effects may be useful for treating symptomatic bradycardia in beta-blocker or calcium channel blocker overdose.
Glucagon should not yet change inotrope practice; leaves open chronotropic utility in overdose for prospective trials.
Glucagon is considered to exert cardiostimulant effects, most notably the enhancement of heart rate and contractility, due to the stimulation of glucagon receptors associated with Gs protein stimulation which causes adenylyl cyclase activation and the consequent increase in 3',5'-cyclic adenosine monophosphate production in the myocardium. These effects have been extensively demonstrated in experimental studies in different animal species. However, efforts to extrapolate the experimental data to patients with low cardiac output states, such as acute heart failure or cardiogenic shock, have been disappointing. The experimental and clinical data on the cardiac effects of glucagon are described here.
No takes yet. Share an insight, caveat, or question.
Jesús Hernández-Cascales (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: